Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Mersana Therapeutics, Inc. (MRSN : NSDQ)
 
 • Company Description   
Mersana Therapeutics, Inc. is a biotechnology company. It focused on discovering and developing a pipeline of antibody drug conjugates. The company's product candidates include XMT-1522 and XMT-1536 which are in clinical stage. Mersana Therapeutics, Inc. is based in CAMBRIDGE, United States.

Number of Employees: 169

 
 • Price / Volume Information   
Yesterday's Closing Price: $3.12 Daily Weekly Monthly
20 Day Moving Average: 1,277,367 shares
Shares Outstanding: 96.99 (millions)
Market Capitalization: $302.61 (millions)
Beta: 2.37
52 Week High: $15.34
52 Week Low: $2.68
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -23.53% -16.21%
12 Week -19.38% -12.52%
Year To Date -49.84% -40.35%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
840 MEMORIAL DRIVE
-
CAMBRIDGE,MA 02139
USA
ph: 617-498-0020
fax: -
ir@mersana.com http://www.mersana.com
 
 • General Corporate Information   
Officers
Anna Protopapas - Chief Executive Officer and President
David Mott - Chairman of the Board
Brian DeSchuytner - Chief Financial Officer
Ashish Mandelia - Vice President
Kristen Hege - Director

Peer Information
Mersana Therapeutics, Inc. (CORR.)
Mersana Therapeutics, Inc. (RSPI)
Mersana Therapeutics, Inc. (CGXP)
Mersana Therapeutics, Inc. (BGEN)
Mersana Therapeutics, Inc. (GTBP)
Mersana Therapeutics, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 59045L106
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/05/22
Share - Related Items
Shares Outstanding: 96.99
Most Recent Split Date: (:1)
Beta: 2.37
Market Capitalization: $302.61 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.53 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.13 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/05/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.85
Price/Cash Flow: -
Price / Sales: 146.26
EPS Growth
vs. Year Ago Period: -18.00%
vs. Previous Quarter: 13.24%
Sales Growth
vs. Year Ago Period: 18,409.09%
vs. Previous Quarter: 18,409.09%
ROE
03/31/22 - -119.10
12/31/21 - -101.42
09/30/21 - -77.17
ROA
03/31/22 - -78.07
12/31/21 - -73.52
09/30/21 - -60.42
Current Ratio
03/31/22 - 4.28
12/31/21 - 3.97
09/30/21 - 4.53
Quick Ratio
03/31/22 - 4.28
12/31/21 - 3.97
09/30/21 - 4.53
Operating Margin
03/31/22 - -8,826.73
12/31/21 - -386,500.03
09/30/21 - -348,653.50
Net Margin
03/31/22 - -8,826.73
12/31/21 - -386,500.03
09/30/21 - -348,653.50
Pre-Tax Margin
03/31/22 - -8,826.73
12/31/21 - -395,488.34
09/30/21 - -348,653.50
Book Value
03/31/22 - 1.45
12/31/21 - 1.69
09/30/21 - 2.17
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.18
12/31/21 - 0.20
09/30/21 - 0.03
Debt-to-Capital
03/31/22 - 14.95
12/31/21 - 16.83
09/30/21 - 3.16
 

Powered by Zacks Investment Research ©